Summit Therapeutics Inc. Stock

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - 00:00:00 08/10/2026 +04 Pre-market 15:11:35
17.95 USD +3.70% Intraday chart for Summit Therapeutics Inc. 17.37 -3.23%

Valuation: Summit Therapeutics Inc.

Market Cap 10.87B 14.36B 12.83B 11.97B 20.47B 1,389B 20.62B 144B 56.18B 706B 53.89B 52.73B 2,270B P/E 2026 *
-15.6x
P/E 2027 * -15.5x
Enterprise Value 10.4B 13.73B 12.27B 11.45B 19.59B 1,329B 19.73B 138B 53.75B 676B 51.56B 50.45B 2,172B EV / Sales 2026 *
3,543x
EV / Sales 2027 * 255x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
09-22 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
09-15 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
09-14 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
09-09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09-09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
08-26 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
08-26 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
08-26 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
08-26 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
08-25 Wall Street Wants Receipts Zonebourse
08-25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
08-12 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
08-12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day-3.23%
1 week+6.15%
Current month+6.15%
1 month+1.96%
3 months+13.04%
6 months-6.61%
Current year+2.63%
1 week 16.44
Extreme 16.44
18.33
1 month 15.18
Extreme 15.18
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 55 11/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
04/06/26 Buy

Chief Executive Officer

100,000 0.0129%
04/06/26 Buy

Chief Executive Officer

100,000 0.0129%
04/06/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+3.70%+6.15%-19.47%+919.89% 14.36B
+4.16%+4.16%+49.37%+94.17% 74.68B
-15.79%-16.05%+2.81%+51.28% 58.7B
-1.80%+1.18%+4.11%+32.21% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -2.04%-1.35%+36.49%+229.36% 40.05B
Weighted average by Cap. -2.08%-1.29%+46.78%+172.72%

Financials

2026 *2027 *
Net sales 2.94M 3.88M 3.46M 3.23M 5.53M 375M 5.57M 38.83M 15.17M 191M 14.55M 14.24M 613M 41.88M 55.31M 49.42M 46.11M 78.88M 5.35B 79.47M 554M 216M 2.72B 208M 203M 8.75B
Net income -701M -925M -827M -771M -1.32B -89.51B -1.33B -9.27B -3.62B -45.52B -3.47B -3.4B -146B -743M -981M -877M -818M -1.4B -94.93B -1.41B -9.83B -3.84B -48.28B -3.68B -3.6B -155B
Net Debt -470M -621M -555M -517M -885M -60.04B -892M -6.22B -2.43B -30.53B -2.33B -2.28B -98.15B -200M -264M -236M -220M -377M -25.57B -380M -2.65B -1.03B -13B -992M -971M -41.8B
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
07/10/26 $17.95 +3.70% 8,175,297
06/10/26 $17.31 +0.23% 5,875,829
05/10/26 $17.27 +3.07% 5,277,704
02/10/26 $16.76 +0.39% 5,196,190
01/10/26 $16.69 -1.30% 7,900,981
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.59GBP
Average target price
22.51GBP
Spread / Average Target
+65.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock